The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / New Tools for Myositis Diagnosis, Classification & Management

New Tools for Myositis Diagnosis, Classification & Management

April 15, 2019 • By Susan Bernstein

  • Tweet
  • Email
Print-Friendly Version / Save PDF
courtesy ACR Daily News

courtesy ACR Daily News

CHICAGO—At Hot Topics in Myositis, a session at the 2018 ACR/ARHP Annual Meeting, three experts discussed new classification criteria for idiopathic inflammatory myopathies (IIM) and offered practical primers on overlap myositis conditions and inclusion body myositis (IBM).

You Might Also Like
  • Tips for Myositis Management
  • Myositis AutoantibodiesTriggered by Statins
  • Myositis Autoantibodies as Biomarkers
Explore This Issue
April 2019
Also By This Author
  • Ellen M. Gravallese, MD, Begins ACR Presidency

New Myositis Classification Criteria

After a 10-year development process, the new EULAR/ACR Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups was published in 2017.1 These criteria reflect updated knowledge of the myositis disease spectrum and included 976 myositis cases and 624 comparators contributed by 47 rheumatology, dermatology, neurology and pediatric clinics worldwide, said Ingrid E. Lundberg, MD, PhD, a professor in the Division of Rheumatology at Karolinska Institute, Karolinska University Hospital, Sweden.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Inflammatory myopathies are a heterogeneous group of diseases, now with several subdiagnoses that have been identified. There are a number of new autoantibodies that have been identified. It’s recognized that extramuscular organ involvement is frequently seen in patients,” said Dr. Lundberg.

The new criteria score variables in a case to determine the probability a patient has one of several IIM conditions. Variables include age of first symptom onset; clinical muscle symptoms, such as weakness; skin variables, such as heliotrope rash or Gottron’s papules; other clinical variables, such as dysphagia or esophageal dysmotility; laboratory variables, such as elevated serum creatine kinase (CK) and other muscle enzymes, as well as positivity for autoantibodies, such as anti-Jo-1; and muscle biopsy results. Each variable is weighted differently on the basis of whether the patient does or does not have muscle biopsy data. The criteria development committee recommended having 55% probability as a lower limit for classification, or a score of 5.5 without a muscle biopsy and 6.7 with biopsy. A patient with 90% probability is classified as a definite myositis case.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

‘A normal CK does not exclude myositis.’ —Ingrid E. Lundberg, MD, PhD

A flow chart helps users subclassify patients with a confirmed IIM: They first consider the patient’s age of disease onset; patients under 18 years old are subclassified as having juvenile dermatomyositis (JDM) if they have a skin rash and juvenile myositis if they do not have a rash. Patients over 18 years old with a skin rash and muscle weakness are classified as having dermatomyositis (DM), and those without muscle weakness as having amyopathic DM.

Patients over 18 years old without the typical skin rash but with such clinical features as finger flexor weakness or rimmed vacuoles are classified with inclusion-body myositis, “whereas patients without these features end up in the group with polymyositis [PM],” said Dr. Lundberg. A free, online criteria calculator is available.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 6 7 8 | Single Page

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: 2018 ACR/ARHP Annual Meeting, fibrosing myopathy, idiopathic inflammatory myopathies, inclusion body myositis (IBM), overlap myositisIssue: April 2019

You Might Also Like:
  • Tips for Myositis Management
  • Myositis AutoantibodiesTriggered by Statins
  • Myositis Autoantibodies as Biomarkers
  • ACR 2013 State-of-the-Art Clinical Symposium: How to Identify Signs of Myositis and Metabolic Myopathies

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)